<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01158846</url>
  </required_header>
  <id_info>
    <org_study_id>Biva/Pra versus Abcix/clop</org_study_id>
    <secondary_id>B/P vs A/C for STEMI</secondary_id>
    <secondary_id>Biva/Pra versus Abcix/clop</secondary_id>
    <secondary_id>Biva/Pra versus Abcix/clop</secondary_id>
    <nct_id>NCT01158846</nct_id>
  </id_info>
  <brief_title>Bivalirudin/Prasugrel Versus Abciximab/Clopidogrel in Patients Presenting With STEMI</brief_title>
  <official_title>Bivalirudin Plus Prasugrel vs Abciximab Plus Clopidogrel. Optimizing Ischemic Protection and Bleeding Risk in Patients With ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Sant'Ambrogio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centro Cardiologico Monzino</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera Niguarda CÃ  Granda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Istituto Clinico Sant'Ambrogio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the setting of ST elevation myocardial infarction newer therapies has been recently
      studied and, following encouraging results, introduced into the clinical practice. Prasugrel
      showed to be a valid alternative to overcome limitation of clopidogrel therefore providing a
      better ischemic protection. On the other hand, bivalirudin is at least as beneficial as
      heparin/abciximab as anticoagulant agent but associated with fewer hemorrhagic events. The
      primary hypothesis of the study is that the combination of prasugrel plus bivalirudin can be
      associated with a better risk/benefit profile.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      In the setting of STEMI, adjunctive pharmacological therapy plays a key role in the acute
      management. Along with the clear benefit of mechanical reperfusion strategies, several drugs
      showed to be beneficial. On top of clopidogrel, heparins and IIB/IIIa glycoprotein, other
      drugs have been recently introduced showing encouraging results. These &quot;new&quot; drugs, namely
      prasugrel and bivalirudin, have only been compared separately.

      Primary hypothesis: the combination of prasugrel/bivalirudin is superior to the combination
      of clopidogrel and heparin/abciximab in terms of net adverse clinical events, i.e. ischemic
      events plus hemorrhagic events

      Setting:

      - patients presenting with ST-elevation myocardial infarction undergoing primary PCI

      Mechanical reperfusion:

      -primary percutaneous coronary intervention

      Pharmacological Interventions:

      - Two arms: Clopidogrel plus heparin/abciximab vs Prasugrel plus Bivalirudin

      Follow up:

      - 1 year

      Measurements:

        -  efficacy end points in terms of reduction of ischemic events

        -  safety end points in terms of reduction of bleeding events
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>major adverse cardiovascular events</measure>
    <time_frame>1 year</time_frame>
    <description>Combined outcome of overall death, non fatal MI, major stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>major bleedings</measure>
    <time_frame>1 year</time_frame>
    <description>according to TIMI major bleedings definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>minor bleedings</measure>
    <time_frame>1 year</time_frame>
    <description>according to TIMI minor bleedings definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent thrombosis</measure>
    <time_frame>1 year</time_frame>
    <description>according to ARC definition of probable/definite stent thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall death</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non fatal myocardial infarction</measure>
    <time_frame>1 year</time_frame>
    <description>defined according to current guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ischemic stroke</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>ST-Elevation Myocardial Infarction</condition>
  <condition>Primary Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>prasugrel/bivalirudin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60 mg loading dose of prasugrel will be followed by maintenance dose of 10mg (or 5mg according to body weight and age). During primary PCI, Bivalirudin will be used as anticoagulant (bolus plus infusion), on a weight-adjusted dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>clopidogrel/abciximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600mg loading dose of clopidogrel will be followed by 75mg maintenance dose. During primary PCI abciximab (bolus plus infusion) will be used as anticoagulant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prasugrel/bivalirudin</intervention_name>
    <description>60mg loading dose followed by 10mg or 5 mg (according to body weight or age)maintenance dose of prasugrel. Bivalirudin during the primary PCI (bolus plus infusion)</description>
    <arm_group_label>prasugrel/bivalirudin</arm_group_label>
    <other_name>Efient</other_name>
    <other_name>Angiox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel/abciximab</intervention_name>
    <description>600mg loading dose of clopidogrel followed by 75mg maintenance dose. Abciximab will be used during primary PCI, bolus plus infusion.</description>
    <arm_group_label>clopidogrel/abciximab</arm_group_label>
    <other_name>Plavix</other_name>
    <other_name>ReoPro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ST elevation myocardial infarction

          -  No contraindication to primary PCI

        Exclusion Criteria:

          -  Known intolerance/allergy to one of the study drugs or their components

          -  Clinical indication to treatment with oral anticoagulant, including use of warfarin or
             dabigatran or other oral anticoagulant agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Testa, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico S. Ambrogio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fracensco Bedogni, MD</last_name>
    <role>Study Director</role>
    <affiliation>Istituto Clinico S. Ambrogio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luca Testa, MD, PhD</last_name>
    <phone>+39-3490808660</phone>
    <email>luctes@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istituto Clinico S. Ambrogio</name>
      <address>
        <city>Milan</city>
        <zip>20149</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Testa, MD, PhD</last_name>
      <phone>+39-3490808660</phone>
      <email>luctes@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Luca Testa, Md, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesco Bedogni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM; TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009 Feb 28;373(9665):723-31. doi: 10.1016/S0140-6736(09)60441-4.</citation>
    <PMID>19249633</PMID>
  </reference>
  <reference>
    <citation>Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW; HORIZONS-AMI Trial Investigators. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet. 2009 Oct 3;374(9696):1149-59. doi: 10.1016/S0140-6736(09)61484-7. Epub 2009 Aug 28.</citation>
    <PMID>19717185</PMID>
  </reference>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2010</study_first_submitted>
  <study_first_submitted_qc>July 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2010</study_first_posted>
  <last_update_submitted>July 7, 2010</last_update_submitted>
  <last_update_submitted_qc>July 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Luca Testa</name_title>
    <organization>Istituto Clinico S.Ambrogio</organization>
  </responsible_party>
  <keyword>STEMI</keyword>
  <keyword>Primary PCI</keyword>
  <keyword>anticoagulants</keyword>
  <keyword>antiplatelets</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Abciximab</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
    <mesh_term>Hirudins</mesh_term>
    <mesh_term>Bivalirudin</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin Fab Fragments</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

